Cargo Therapeutics (Cargo Therapeutics) ROCE % : -34.45% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cargo Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2024 was -34.45%.

Cargo Therapeutics ROCE % Historical Data

The historical data trend for Cargo Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics ROCE % Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-284.67

-48.52

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial				-	-220.46	-385.20	-54.24	-34.45

Cargo Therapeutics ROCE % Calculation

Cargo Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-96.543	/	( ( (10.243 - 44.137)	+	(453.036 - 21.162) )	/ 2 )
	=	-96.543	/	( (-33.894	+	431.874)	/ 2 )
	=	-96.543	/	198.99
	=	-48.52 %

Cargo Therapeutics's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-143.244	/	( ( (453.036 - 21.162)	+	(422.429 - 22.649) )	/ 2 )
	=	-143.244	/	( ( 431.874	+	399.78 )	/ 2 )
	=	-143.244	/	415.827
	=	-34.45 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Cargo Therapeutics (NAS:CRGX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cargo Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics (Cargo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing strategy are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. Their lead program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

Cargo Therapeutics (Cargo Therapeutics) Headlines

From GuruFocus

CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors

By Marketwired • 04-15-2024